Display options
Cite
Lichtinghagen R, Musholt PB, Lein M, et al. Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur Urol. 2002;42(4):398-406doi: 10.1016/s0302-2838(02)00324-x.
Lichtinghagen, R., Musholt, P. B., Lein, M., Römer, A., Rudolph, B., Kristiansen, G., Hauptmann, S., Schnorr, D., Loening, S. A., & Jung, K. (2002). Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. European urology, 42(4), 398-406. https://doi.org/10.1016/s0302-2838(02)00324-x
Lichtinghagen, Ralf, et al. "Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue." European urology vol. 42,4 (2002): 398-406. doi: https://doi.org/10.1016/s0302-2838(02)00324-x
Lichtinghagen R, Musholt PB, Lein M, Römer A, Rudolph B, Kristiansen G, Hauptmann S, Schnorr D, Loening SA, Jung K. Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur Urol. 2002 Oct;42(4):398-406. doi: 10.1016/s0302-2838(02)00324-x. PMID: 12361907.
Copy Download .nbib Format: NLM
Share it on

Eur Urol. 2002 Oct;42(4):398-406. doi: 10.1016/s0302-2838(02)00324-x.

Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue.

European urology

Ralf Lichtinghagen, Petra B Musholt, Michael Lein, Andreas Römer, Birgit Rudolph, Glen Kristiansen, Steffen Hauptmann, Dietmar Schnorr, Stefan A Loening, Klaus Jung

Affiliations

  1. Department of Clinical Chemistry, University Medical School, Hannover, Germany.

PMID: 12361907 DOI: 10.1016/s0302-2838(02)00324-x

Abstract

OBJECTIVE: The aim of this study was to assess the behavior of the matrix metalloproteinases (MMPs) 2 and 9 and the tissue inhibitor of metalloproteinases 1 (TIMP-1) in human prostate cancer.

METHODS: mRNA and protein expression patterns of MMP-2, MMP-9, and TIMP-1 were studied in cancerous and noncancerous parts of 17 prostates removed by radical prostatectomy. Competitive RT-PCR, gelatin-substrate zymography, and ELISA techniques were used for quantification.

RESULTS: On the mRNA level, MMP-2 expression was decreased and MMP-9, TIMP-1, the ratios of MMP-2 and MMP-9 to TIMP-1 were unchanged in cancerous tissue compared to the normal counterparts. On the protein level, expression of MMP-9 was significantly higher and TIMP-1 expression was significantly lower, MMP-2 was unchanged and the ratios of MMP-2 and MMP-9 to TIMP-1 were increased in tumor tissue.

CONCLUSIONS: The higher concentration of MMP-9 as well as the increased ratios of MMP-2 and MMP-9 to TIMP-1 in malignant tissue prove the proteolytic dysbalance in prostate cancer, which does not seem to be associated with the stage and grade of the tumor. Comparison of mRNA and protein expression of MMP-2, MMP-9 and TIMP-1, respectively, did not show any significant relationships illustrating the necessity to study these components at both molecular levels.

Copyright 2002 Elsevier Science B.V.

Substances

MeSH terms

Publication Types